{"groups":[{"description":"Participants received one of the following chemotherapies at the discretion of the investigator: paclitaxel, 80 milligrams per square meter (mg/m\\^2) as a 1-hour intravenous (IV) infusion on Days 1, 8, 15, and 22 every 4 weeks (q4w) OR topotecan 4 mg/m\\^2 as a 30-minute IV infusion on Days 1, 8, and 15 q4w (alternatively, a 1.25 mg/m\\^2 dose could have been administered over 30 minutes on Days 1-5 every 3 weeks \\[q3w\\]) OR pegylated liposomal doxorubicin (PLD) 40 mg/m\\^2 as a 1 milligram per minute (mg/min) infusion on Day 1 q4w (after Cycle 1 the drug could have been administered as a 1 hour infusion). Depending on chosen chemotherapy, pre-medication was implemented according to local practices.","id":"FG000","title":"Chemotherapy"},{"description":"Participants received one of the following chemotherapies at the discretion of the investigator: paclitaxel, 80 mg/m\\^2 as a 1-hour IV infusion on Days 1, 8, 15, and 22 q4w OR topotecan 4 mg/m\\^2 as a 30-minute IV infusion on Days 1, 8, and 15 q4w (alternatively, a 1.25 mg/m\\^2 dose could have been administered over 30 minutes on Days 1-5 q3w) OR PLD 40 mg/m\\^2 as a 1 mg/min infusion on Day 1 q4w (after Cycle 1 the drug could have been administered as a 1 hour infusion. Depending on chosen chemotherapy, pre-medication was implemented according to local practices. The chosen chemotherapy was combined with bevacizumab 10 milligrams per kilogram (mg/kg) IV every 2 weeks (q2w; or bevacizumab 15 mg/kg q3w if used in combination with topotecan 1.25 mg/m\\^2 on Days 1-5 on a q3w schedule). The initial bevacizumab infusion was over 90 minutes, with subsequent infusions over 60 minutes and then 30 minutes, as tolerated.","id":"FG001","title":"Chemotherapy + Bevacizumab"}],"periods":[{"dropWithdraws":[{"reasons":[{"groupId":"FG000","numSubjects":"4"},{"groupId":"FG001","numSubjects":"6"}],"type":"Withdrawal by Subject"},{"reasons":[{"groupId":"FG000","numSubjects":"138"},{"groupId":"FG001","numSubjects":"126"}],"type":"Death"},{"reasons":[{"groupId":"FG000","numSubjects":"0"},{"groupId":"FG001","numSubjects":"1"}],"type":"Adverse Event"},{"reasons":[{"groupId":"FG000","numSubjects":"2"},{"groupId":"FG001","numSubjects":"0"}],"type":"Protocol Violation"},{"reasons":[{"groupId":"FG000","numSubjects":"8"},{"groupId":"FG001","numSubjects":"9"}],"type":"Other"},{"reasons":[{"groupId":"FG000","numSubjects":"30"},{"groupId":"FG001","numSubjects":"37"}],"type":"In Follow-Up as of 25 Jan 2013"}],"milestones":[{"achievements":[{"groupId":"FG000","numSubjects":"182"},{"groupId":"FG001","numSubjects":"179"}],"type":"STARTED"},{"achievements":[{"comment":"At time of clinical cutoff for overall survival and safety (25 January 2013)","groupId":"FG000","numSubjects":"0"},{"comment":"At time of clinical cutoff for overall survival and safety (25 January 2013)","groupId":"FG001","numSubjects":"0"}],"type":"COMPLETED"},{"achievements":[{"groupId":"FG000","numSubjects":"182"},{"groupId":"FG001","numSubjects":"179"}],"type":"NOT COMPLETED"}],"title":"Overall Study"}]}